Days after Neuraxpharm announced that it had acquired the narcolepsy brands Provigil (modafinil) and Nuvigil (armodafinil) in the majority of non-US markets, the fate of the drugs’ US rights has been revealed.
Apotex Remains Alert To Acquire US Provigil And Nuvigil Rights
Deal Follows Neuraxpharm Buying Up Narcolepsy Drugs In Most Non-US Markets
A decade after Teva was slapped with a ten-figure fine for its alleged illegal activities blocking US generic competition to its Provigil brand, the Israeli firm has offloaded the narcolepsy drug and follow-up brand Nuvigil in the US to Apotex.
More from Deals
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.